HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
18 hedge funds and large institutions have $283K invested in HTG Molecular Diagnostics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.
14% less funds holding
Funds holding: 21 → 18 (-3)
55% less capital invested
Capital invested by funds: $622K → $283K (-$339K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$60.1K |
| 2 |
Millennium Management
New York
|
+$1.08K |
| 3 |
Morgan Stanley
New York
|
+$596 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$97 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.6K |
| 2 |
Renaissance Technologies
New York
|
-$68.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$36.3K |
| 4 |
Citigroup
New York
|
-$21K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $53K | -$68.5K | -5,637 | -44% |
|
2
BlackRock
New York
| $45K | -$1.74K | -143 | -2% |
|
|
VF
3
Virtu Financial
New York
| $44K | +$60.1K | +4,944 | +452% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $43K | -$4.56K | -375 | -6% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $28K | – | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $17K | -$72.6K | -5,967 | -72% |
|
|
7
Millennium Management
New York
| $15K | +$1.08K | +89 | +5% |
|
|
TSS
8
Two Sigma Securities
New York
| $13K | -$36.3K | -2,982 | -62% |
|
9
State Street
Boston,
Massachusetts
| $9K | – | – | – |
|
|
10
Morgan Stanley
New York
| $7K | +$596 | +49 | +6% |
|
|
HWM
11
HighMark Wealth Management
St. Paul,
Minnesota
| $4K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $3K | -$657 | -54 | -13% |
|
|
AF
13
Allworth Financial
Folsom,
California
| $2K | – | – | – |
|
|
14
Citigroup
New York
| – | -$21K | -1,719 | Closed |
|
15
JP Morgan Chase
New York
| – | -$365 | -30 | -94% |
|
|
16
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$97 | +8 | New |
|
HTGM Hedge Fund Activity: Q3 2022 in Review
18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2022, worth a combined $283K — down 55% from $622K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of HTGM and 1 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, adding an estimated $60.1K. The largest seller was Susquehanna International Group, cutting an estimated $72.6K.
- 18 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2022, down from 21 in Q2 2022.
- Funds reported $283K of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2022, down 55% quarter-over-quarter.
- 1 fund opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -3 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2022 was Virtu Financial, an estimated $60.1K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2022 was Susquehanna International Group, an estimated $72.6K sold.
Based on aggregated 13F filings for Q3 2022.